Understanding C Peptide as a Diagnostic Marker

The diagnosis of pancreatic tumors, particularly insulinomas, presents a clinical challenge that often hinges on subtle metabolic clues. Among the most reliable biomarkers available to endocrinologists and gastroenterologists is C peptide, a small protein fragment produced during the synthesis of insulin. Measuring C peptide levels in the blood provides a direct window into endogenous insulin production, making it an indispensable tool for distinguishing between tumors that overproduce insulin and other causes of hypoglycemia. This article examines the role of C peptide as a marker for detecting insulinoma and other pancreatic neoplasms, covering its biochemical basis, clinical application, and diagnostic performance.

Insulinomas are rare neuroendocrine tumors that arise from the beta cells of the pancreas. They typically present with recurrent episodes of hypoglycemia, often misattributed to other conditions before the correct diagnosis is reached. Because these tumors secrete insulin autonomously, they produce a characteristic biochemical profile: elevated insulin levels coupled with elevated C peptide levels during hypoglycemia. Understanding this relationship is essential for clinicians managing patients with unexplained low blood glucose.

What Is C Peptide? A Biochemical Overview

C peptide, also known as connecting peptide, is a 31-amino acid polypeptide that serves as a byproduct of insulin synthesis within the pancreatic beta cells. When proinsulin is cleaved to form mature insulin, C peptide is released into the bloodstream in equimolar amounts. This means that for every molecule of insulin secreted, one molecule of C peptide is also released. Unlike insulin, which is rapidly cleared by the liver and has a short half-life of approximately 3-5 minutes, C peptide is cleared more slowly by the kidneys and has a half-life of 20-30 minutes. These pharmacokinetic differences make C peptide a more stable and reliable marker of beta cell activity than insulin itself.

Historically, C peptide was considered an inactive metabolic byproduct, but research has uncovered potential biological activities, including binding to cell surface receptors and influencing vascular function. However, its primary clinical value remains its role as a reporter of endogenous insulin secretion. Under normal physiological conditions, C peptide levels rise after meals in response to glucose stimulation and fall during fasting. In pathological states such as insulinoma, this regulation is lost, leading to persistently elevated C peptide levels even when blood glucose is dangerously low.

Measuring C peptide requires a simple blood test, typically performed using chemiluminescent immunoassay or radioimmunoassay. Laboratories report results in nanograms per milliliter or picomoles per liter, with normal fasting values generally below 0.2 nmol/L or around 0.9-1.8 ng/mL, though reference ranges vary by assay and population.

The Clinical Rationale for Measuring C Peptide

The primary indication for C peptide measurement is the evaluation of hypoglycemia, especially when the cause is unclear. Hypoglycemia can result from numerous mechanisms: excessive insulin or insulin-like growth factor production, liver disease, adrenal insufficiency, sepsis, drugs, or accidental or surreptitious insulin administration. Differentiating among these possibilities requires careful biochemical interpretation, and C peptide plays a central role in this process.

When a patient presents with documented hypoglycemia (plasma glucose less than 55 mg/dL or 3.0 mmol/L with accompanying symptoms), a critical blood sample should be obtained to measure glucose, insulin, C peptide, proinsulin, and, in some cases, beta-hydroxybutyrate and sulfonylurea levels. The relationship between these values determines the likely etiology.

Elevated C peptide levels during hypoglycemia indicate that the beta cells are actively secreting insulin, arguing against exogenous insulin administration, which suppresses endogenous production. In the setting of an insulinoma, both insulin and C peptide are elevated. This pattern can also be seen in patients taking sulfonylurea drugs, which stimulate beta cell secretion, necessitating a sulfonylurea screen to exclude drug-induced hypoglycemia. Conversely, low C peptide levels with low insulin suggest that the hypoglycemia is not driven by insulin excess and point toward alternative causes such as adrenal insufficiency, liver disease, or non-islet cell tumors producing IGF-2.

Critical Diagnostic Thresholds

During a supervised fasting test, the following criteria are commonly used to diagnose insulinoma: plasma glucose less than 55 mg/dL, insulin greater than 3 microIU/mL, C peptide greater than or equal to 0.2 nmol/L, and proinsulin elevated. However, because different laboratories use different assays, clinicians must interpret results relative to their own institution's reference ranges. A C peptide level that is inappropriately normal or elevated during hypoglycemia is the key finding. In healthy individuals, C peptide falls to very low levels as glucose drops, and any detectable C peptide during significant hypoglycemia is abnormal.

Pathophysiology of Insulinoma and C Peptide Secretion

Insulinomas typically arise sporadically, though they may occur as part of multiple endocrine neoplasia type 1. Most are small, solitary, benign adenomas less than 2 cm in diameter, located within the pancreas. Malignant insulinomas account for approximately 5-10% of cases and tend to be larger. The defining characteristic of these tumors is their loss of normal glucose-sensing feedback: they secrete insulin autonomously, driven by constitutive secretory activity rather than the prevailing blood glucose concentration.

Because C peptide is co-secreted with insulin in equimolar amounts, its measurement provides a surrogate for insulin secretion that is not confounded by the presence of exogenous insulin or insulin antibodies. This is particularly advantageous because many patients with insulinoma have already received glucose or glucagon before a diagnosis is suspected, and exogenous insulin may have been administered during initial management. In these scenarios, C peptide levels remain reliable indicators of endogenous production, whereas measured insulin may be misleading.

The autonomy of insulin secretion in insulinoma means that C peptide and insulin remain detectable even when glucose falls to hypoglycemic levels. This stands in contrast to the normal physiological response, in which low glucose suppresses insulin release and, consequently, C peptide levels. Thus, the simultaneous presence of hypoglycemia with measurable C peptide is a hallmark of inappropriate insulin secretion.

Supervised Fasting Test: The Gold Standard

For patients with suspected insulinoma, the 72-hour supervised fasting test remains the diagnostic gold standard, guided by protocols established by the Endocrine Society. The test is performed under strict medical supervision in a hospital setting, with frequent monitoring of blood glucose and symptoms. When glucose falls below 55 mg/dL and the patient exhibits neuroglycopenic symptoms, blood is drawn for the critical sample: glucose, insulin, C peptide, proinsulin, beta-hydroxybutyrate, and sulfonylurea screen.

More than 90% of patients with insulinoma develop hypoglycemia within the first 24 hours of fasting, and virtually all do so by 72 hours. The test can be terminated earlier if the diagnostic criteria are met. During the fast, only water is permitted, and the patient must be observed for signs of hypoglycemia. It is essential that the critical sample include C peptide measurement to confirm that the hypoglycemia is driven by endogenous insulin.

An elevated C peptide level during fasting hypoglycemia strongly supports the diagnosis of insulinoma, provided that exogenous insulin use and sulfonylurea ingestion have been excluded. Some protocols also measure proinsulin, which may be disproportionately elevated in insulinoma because of defective proinsulin processing within tumor cells. Combining C peptide, insulin, and proinsulin measurements increases diagnostic sensitivity.

Alternative Testing Strategies

In patients unable to tolerate prolonged fasting or with episodic symptoms, alternative approaches include the mixed meal test, in which a patient consumes a standardized meal and glucose, insulin, and C peptide are measured over several hours. Insulinoma patients may exhibit hypoglycemia 3-5 hours after the meal, with persistent C peptide secretion. Another approach is the C peptide suppression test, in which exogenous insulin is administered and the degree of suppression of endogenous C peptide is measured. In insulinoma, C peptide fails to suppress appropriately because the tumor's secretory activity is not regulated by glucose or by feedback inhibition.

Differential Diagnosis: Using C Peptide to Distinguish Causes

The differential diagnosis of hyperinsulinemic hypoglycemia includes insulinoma, sulfonylurea use, insulin autoimmune syndrome, and, rarely, conditions such as post-gastric bypass hypoglycemia. C peptide is central to this distinction.

In exogenous insulin administration, the insulin level is high but C peptide is low. This pattern reflects the body's suppression of endogenous insulin production in response to supraphysiologic insulin levels. The presence of insulin antibodies on laboratory testing can further confirm this scenario. Sulfonylurea-induced hypoglycemia mimics insulinoma biochemically because both insulin and C peptide are elevated. A sulfonylurea screen is required to differentiate the two; positive results indicate drug effect rather than tumor. Insulin autoimmune syndrome is characterized by high insulin levels, detectable insulin antibodies, and variable C peptide levels, but the mechanism involves antibody binding rather than autonomous secretion, so C peptide may be elevated or suppressed depending on the phase.

Post-gastric bypass hypoglycemia typically occurs in the postprandial setting and is characterized by elevated C peptide and insulin after meals, though fasting hypoglycemia is less common. In contrast, insulinoma typically presents with fasting hypoglycemia, though some patients experience mixed patterns. The clinical history and timing of symptoms are crucial for interpretation.

C Peptide in the Detection of Other Pancreatic Tumors

While C peptide is most strongly associated with insulinoma, it can provide useful information in the evaluation of other pancreatic tumors. Pancreatic neuroendocrine tumors arise from various cell types within the islets of Langerhans and may secrete a range of hormones, including gastrin, glucagon, vasoactive intestinal peptide, or somatostatin. Although these tumors do not typically produce C peptide, their presence can disrupt normal islet architecture and function, potentially altering insulin and C peptide secretion indirectly.

In the case of glucagonomas, which secrete glucagon, the hyperglycemic state may lead to secondary beta cell dysfunction, and C peptide levels may be elevated as a compensatory response to counter hyperglycemia. However, C peptide is not used as a primary diagnostic marker for these tumors. Gastrinomas are typically diagnosed by measuring gastrin levels and performing secretin stimulation testing. VIPomas are diagnosed by vasoactive intestinal peptide measurement. In each case, C peptide plays a supportive rather than diagnostic role.

More recently, attention has focused on the utility of C peptide in the setting of pancreatic adenocarcinoma. Epidemiologic studies have linked elevated fasting C peptide levels with increased risk of pancreatic cancer, potentially mediated by the growth-promoting effects of insulin and IGF-1. Observational data suggest that hyperinsulinemia, reflected by elevated C peptide, may be an independent risk factor for the development of pancreatic cancer, although the effect is modest and confounded by obesity and metabolic syndrome. At present, C peptide is not recommended as a screening test for pancreatic adenocarcinoma, but it may have a role in understanding the metabolic environment that promotes tumorigenesis.

Interpreting C Peptide Results: Pitfalls and Limitations

Despite its utility, C peptide measurement has limitations that clinicians must recognize. Renal function significantly affects C peptide clearance; patients with chronic kidney disease may have elevated C peptide levels due to reduced renal excretion, leading to false-positive results if interpreted without adjustment. In such patients, alternative markers or adjusted reference ranges may be necessary. Hemolysis in blood samples can interfere with immunoassays and produce spurious results. Additionally, heterophilic antibodies and human anti-animal antibodies may interfere with certain assay formats, causing falsely elevated or depressed readings.

The timing of the sample relative to glucose administration is critical. If a hypoglycemic patient is given glucose or glucagon before the critical blood draw, the insulin and C peptide levels may rise in response to the glucose, producing a pattern that may be misinterpreted as primary hypersecretion. For this reason, the critical sample must be obtained before glucose is administered whenever possible.

Interpretation must also account for the half-life difference between insulin and C peptide. Because C peptide persists longer in circulation, its levels may not reflect acute fluctuations in insulin secretion. In the context of episodic hypoglycemia, a single C peptide measurement may not capture the relevant window of secretion if the sample is drawn too early or too late relative to the hypoglycemic episode.

Imaging and Localization After Biochemical Diagnosis

Once C peptide and insulin levels have confirmed endogenous hyperinsulinism, the next step is localization of the tumor. Most insulinomas are small and may not be visible on conventional cross-sectional imaging. High-resolution computed tomography with pancreatic protocol can detect many insulinomas, but sensitivity depends on tumor size and contrast timing. Endoscopic ultrasound has emerged as a highly sensitive modality, particularly for small tumors within the pancreatic head and uncinate process. Intraoperative ultrasound is often used to confirm the location during surgery.

C peptide measurement has also been adapted for use in regionalization studies. By measuring C peptide levels in pancreatic venous sampling, the surgeon can localize the region of hypersecretion. However, this invasive technique is reserved for cases where noninvasive methods have failed.

Treatment Implications of C Peptide Monitoring

Successful surgical resection of insulinoma resolves hypoglycemia and normalizes C peptide levels. In patients with unresectable, metastatic, or recurrent disease, medical management focuses on controlling symptoms and suppressing insulin secretion. Diazoxide, a potassium channel activator, directly inhibits insulin release and lowers C peptide levels. Octreotide and lanreotide, somatostatin analogs, can also reduce insulin secretion in some patients. Everolimus, an mTOR inhibitor, has shown efficacy in reducing hypoglycemic episodes in advanced insulinoma, though its effects on C peptide are variable.

Monitoring C peptide levels during follow-up can provide early evidence of tumor recurrence or disease progression. Although imaging remains the mainstay of surveillance, a rising C peptide level in a previously treated patient should prompt investigation for recurrent disease. In the context of metastatic insulinoma, serial C peptide measurements can help assess response to therapy.

C Peptide, Insulinoma, and the Broader Pancreatic Tumor Landscape

The role of C peptide extends beyond the immediate diagnosis of insulinoma. As a marker of beta cell function, it provides insight into the metabolic state of the pancreas in the presence of other diseases. In chronic pancreatitis, for example, C peptide levels may decline as beta cell mass is lost, contributing to the development of diabetes. In pancreatic cystic neoplasms, C peptide levels are not typically used, though some case reports have described coexisting insulinomas and cystic lesions.

Emerging research is exploring the relationship between C peptide and the microbiome in pancreatic cancer patients, as well as the potential for C peptide to serve as a prognostic marker in diabetes mellitus type 2 with pancreatic involvement. For the clinician, the key message is that C peptide is a specific and sensitive marker of endogenous insulin secretion, and its measurement in the appropriate clinical context can be lifesaving.

Practical Recommendations for Clinicians

Based on current evidence and Endocrine Society guidelines, the following recommendations apply when evaluating patients for possible insulinoma or other pancreatic tumors with hypoglycemia:

  • Obtain a critical blood sample during documented hypoglycemia (glucose less than 55 mg/dL with symptoms), before administering glucose if safely possible. The sample should include glucose, insulin, C peptide, proinsulin, beta-hydroxybutyrate, and a sulfonylurea screen.
  • Interpret C peptide in context: an elevated C peptide during hypoglycemia indicates endogenous hyperinsulinism and requires further evaluation for insulinoma or sulfonylurea use.
  • Consider renal function when interpreting results. In patients with kidney disease, use caution and consider alternative approaches or adjusted thresholds.
  • Perform a supervised fasting test if the initial evaluation is inconclusive. This remains the diagnostic gold standard and provides the most definitive evidence of inappropriate insulin secretion.
  • Exclude surreptitious drug use by obtaining a comprehensive toxicology screen, including sulfonylureas, in all patients with unexplained hyperinsulinemic hypoglycemia.
  • Localize the tumor with appropriate imaging only after biochemical confirmation. Avoid imaging before biochemical testing, as incidental pancreatic lesions are common and may lead to unnecessary interventions.

Conclusion

C peptide is far more than a passive byproduct of insulin synthesis. It is a robust, clinically valuable biomarker that stands at the center of the diagnostic evaluation for insulinoma and other pancreatic tumors associated with disordered insulin secretion. By providing a direct measure of endogenous beta cell activity that is not confounded by exogenous insulin, C peptide measurement enables clinicians to differentiate among the many causes of hypoglycemia with confidence. When integrated with fasting testing, imaging, and clinical judgment, C peptide levels guide early detection, appropriate treatment, and effective monitoring of patients with pancreatic neuroendocrine tumors.

For medical professionals across endocrinology, gastroenterology, and surgical oncology, mastering the interpretation of C peptide levels is an essential skill. As research continues to refine the understanding of the metabolic environment in pancreatic disease, C peptide will likely remain a cornerstone of diagnostic reasoning in this challenging clinical area.